Garvey 2006.

Study characteristics
Methods	Study design: parallel RCT Country: USA Recruitment: predominantly through newspaper advertisements
Participants	391 adult smokers; average cigarettes per day: 25
Interventions	1) Placebo 2) Individualised nicotine replacement transdermal patch: dose at 50% nicotine replacement of baseline level 3) Individualised nicotine replacement transdermal patch: dose at 100% nicotine replacement of baseline level 4) 21 mg nicotine patch 5) 42 mg nicotine patch To reach target replacement levels, patch dose was adjusted if necessary during the first 2 weeks post‐cessation for participants assigned to 100% or 50% replacement (i.e. arms 2 and 3 above).
Outcomes	Quit rate at 1‐year follow‐up (no further definition provided) Validation: not reported Adverse events: not reported
Notes	Information extracted from a conference abstract and a secondary publication reporting on unrelated outcomes. Funding: NIDA ‐ DA12165 Conflicts of interest: not reported in conference abstract. Acknowledgements reported in a secondary publication stated: "The authors would like to thank GlaxoSmithKline, Parsippany, New Jersey, for kindly supplying the nicotine (NicoDerm CQ) and placebo patches used in the study. The authors also would like to thank Mary Cooley for assisting in the early conduct phases of the study and Brianna Wadler for editorial help." This study was excluded from previous versions of this review due to insufficient information (Lindson 2019); it was reassessed and deemed eligible and is thus new to this current update version.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "….prospective, randomized, clinical trial…". No further information provided
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Placebo‐controlled but blinding not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not specified